Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JZP898 |
Synonyms | |
Therapy Description |
JZP898 comprises IFNalpha2b linked to half-life extension domains by protease-sensitive linkers that are cleaved to in the presence of proteases in the tumor microenvironment to release IFNalpha2b, potentially inducing IFNalpha signaling and increased anti-tumor immune response (Cancer Res (2023) 83 (7_Supplement):1817). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JZP898 | JZP-898|JZP 898|WTX-613|WTX613 | JZP898 comprises IFNalpha2b linked to half-life extension domains by protease-sensitive linkers that are cleaved to in the presence of proteases in the tumor microenvironment to release IFNalpha2b, potentially inducing IFNalpha signaling and increased anti-tumor immune response (Cancer Res (2023) 83 (7_Supplement):1817). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06108050 | Phase I | JZP898 + Pembrolizumab JZP898 | JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Recruiting | USA | 0 |